Navigation Links
Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Date:5/22/2012

ntly reported rat and dog models confirm Unigene's prior preclinical studies.  These results support the Company's plans to commence Phase 1 clinical testing in obese subjects next year and indicate that, if these results can be reproduced in humans, UGP281 could potentially offer a new and very exciting treatment option in an area that clearly needs new and better treatments."

Nozer Mehta, PhD, Unigene's VP, Research and Development stated, "We are extremely pleased with our progress with UGP281 and continue to build an encouraging preclinical data set for our lead proprietary metabolic peptide."  Dr. Mehta continued, "UGP281's selective receptor-binding is anticipated to result in a cleaner and more attractive safety profile relative to several of the small molecule drug candidates or drug combinations currently, or previously, in development.  We continue to further differentiate UPG281 from other potentially competitive, peptide-based drugs and drug candidates and believe we will have the opportunity to optimally position UGP281 in this rapidly growing and significantly underserved market space."

Unigene is currently preparing for the submission of its Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and expects to be able to commence Phase 1 clinical testing of UGP281 in the first half of 2013.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering peptide drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets inclu
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
3. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
4. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
7. Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
8. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
9. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
10. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
11. Fujifilm Demonstrates the Latest Advancements of Synapse® PACS at RSNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014 Cynosure, ... laser- and light-based aesthetic treatments for non-invasive and minimally invasive ... Executive Vice President, Chief Operating Officer and Chief Financial Officer ... effective August 1, 2014.  Baker, 53, will continue to serve ... Michael Davin , who remains Chairman and Chief Executive ...
(Date:7/30/2014)... 2014  Packaging Coordinators, Inc. (PCI) is pleased to ... Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is headquartered ... United Kingdom and operates regional ... and Tokyo , Japan. Penn Pharma offers ... Commercial dosage form manufacturing, as well as Clinical Packaging, ...
(Date:7/30/2014)... , July 30, 2014   Medical Equipment ... have been awarded a Department of Defense (US Army) ... to supply a mobile MRI diagnostic machine and technical ... Business (WOSB) through the Small Business Administration (SBA), Medical ... the field with the latest medical diagnostic equipment. The ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
... Surgery Foundation Announces Speakers, Moderators and Panelists for 2nd International Symposium on MR-Guided Focused ... CHARLOTTESVILLE, Va. , June ... to speak at the 2nd International Symposium for MR-guided Focused Ultrasound, which will be ... , , , ...
... , SANTA BARBARA, Calif. , June 25 ... Diabetes Research Institute (Sansum) announced today the achievement of a milestone ... Foundation (JDRF). , , ... The world,s most flexible artificial pancreas system platform, currently being used ...
Cached Medicine Technology:Leading Experts to Speak at Focused Ultrasound Symposium 2Leading Experts to Speak at Focused Ultrasound Symposium 3Leading Experts to Speak at Focused Ultrasound Symposium 4Leading Experts to Speak at Focused Ultrasound Symposium 5Leading Experts to Speak at Focused Ultrasound Symposium 6JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 2JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 3JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 4JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 5JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 6
(Date:7/30/2014)... York (PRWEB) July 30, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continues to grow, Bernstein ... voice to those calling for a ban on uterine ... Debra Valverde was diagnosed with leiomyosarcoma following a hysterectomy ... a year of her diagnosis, the aggressive cancer had ...
(Date:7/30/2014)... Bay Aquarium Research Institute (MBARI) have observed a deep-sea ... yearslonger than any other known animal. Throughout this time, ... from predators. This amazing feat represents an evolutionary balancing ... having plenty of time to develop within their eggs, ... little or no food. , Every few months for ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... a garden might help soothe the agitation that commonly strikes ... 17 past studies, British researchers found evidence that watering plants, ... some dementia patients, anxiety. The study authors cautioned that ... subject to study -- and the evidence of a benefit ...
(Date:7/30/2014)... 2014 On July 29, 2014, Freedom ... Institute of Public Health, Gandhinagar released a new report ... II: The Way Forward .” The report was released ... and Practices to Improve Nutrition Security in New Delhi, ... the Green Revolution" and chair of the Coalition ...
(Date:7/30/2014)... July 30, 2014 “North America Contrast ... data on the North America Contrast Media Injectors market. ... and volume (in units) and average price data (in ... Injectors ,     Interventional Cardiology/Angio Injectors and MRI Injectors ... agent) is a substance used to enhance the contrast ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4
... risks of death are probably higher with aprotinin, a drug ... surgery, compared with lysine analogues, according to a study ... of CMAJ . , On December 3, a ... aprotinin use. The study is being early released in advance ...
... A new report from the Institute of Medicine proposes ... decrease the chances of fatigue-related medical errors and to ... The report does not recommend further reducing residents, ... week set by the Accreditation Council for Graduate Medical ...
... /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp., a developer and ... inflammation, announced today that its Board of Directors ... Corporation ("Westaim"), a requisition to call a special ... capital of US$0.80 per share to NUCRYST shareholders. ...
... Health System Builds Resilient, Cost and Energy Efficient Information ... Mass., Dec. 2 EMC Corporation (NYSE: ... today announced that the Daughters of Charity Health System ... California coast, has consolidated storage and servers and implemented ...
... Randomized Comparator Study to Evaluate Efficacy of Commercially ... , WOODCLIFF LAKE, N.J., Dec. 2 ... that it plans to initiate the first clinical ... injection) compared to Vidaza(R) (azacitidine) in adult patients ...
... Dec. 2 Barotz Dental is now one of only ... This is the only laser gum treatment protocol that ... bone tissue around teeth. , ... height of the tissue around teeth, minimizes pain and discomfort ...
Cached Medicine News:Health News:Revised hours and workloads for medical residents needed to prevent 2Health News:Revised hours and workloads for medical residents needed to prevent 3Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 2Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 4Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Barotz Dental Now Offering Laser Gum Therapy 2
... Oxylab pO2 probes feature response ... seconds for real-time monitoring of ... Oxylab LDFTM, measurements of pO2, ... be obtained from the same ...
Spherical Burr for FR030R, 5 mm....
Tungsten Carbide Burr "HM", 0,7 mm, ISO-No. 007....
"Rosen" burr, 0,7 mm, ISO-No. 007....
Medicine Products: